CD38 and systemic sclerosis: In an environment with elevated CD38 activity, such as seen in SSc lesional skin, administering NAD+ precursors or enhancing NAD+ synthesis will have limited effect on increasing NAD+ levels, as elevated CD38 continues to degrade NAD+.